We are submitting hereby copy of newspaper publication of the extract of financial results for the quarter ended 31st March, 2026
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kilitch Drugs India reported strong Q4 FY26 consolidated total income of Rs 89.60 crore, a 46% jump from Rs 61.23 crore in Q4 FY25. Profit after tax for the quarter stood at Rs 14.86 crore compared to Rs 10.22 crore in the same quarter last year. For the full year ended March 2026, consolidated income was Rs 235.47 crore versus Rs 198.32 crore in FY25, showing 19% annual growth. Standalone Q4 PAT was Rs 13.99 crore with full year PAT at Rs 32.40 crore. EPS for the year was Rs 8.91 per share. The results were reviewed by the Audit Committee and approved by the Board on May 15, 2026, and published in newspapers on May 17, 2026.
The company delivered robust year-on-year growth in both revenue and profitability for Q4 and FY26, indicating strong operational performance. The 46% quarterly revenue growth and nearly 20% full-year revenue expansion are positive signals for shareholders.